{"id":"NCT00978627","sponsor":"Novo Nordisk A/S","briefTitle":"Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes","officialTitle":"NN5401-3594: A 26-week, Open-labelled, Two-arm, Parallel, Randomised Trial Comparing Efficacy and Safety of NN5401 Once Daily Plus Insulin Aspart vs. Basal-bolus Treatment With Insulin Detemir Plus Insulin Aspart in Subjects With Type 1 Diabetes / NN5401-3645: An Extension Trial Comparing Safety and Efficacy of NN5401 Plus Meal-time Insulin Aspart for the Remaining Meals With Insulin Detemir Plus Meal-time Insulin Aspart in Type 1 Diabetes (BOOSTâ„¢: T1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2010-05","completion":"2010-05","firstPosted":"2009-09-17","resultsPosted":"2015-11-20","lastUpdate":"2017-03-20"},"enrollment":548,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"insulin degludec/insulin aspart","otherNames":[]},{"type":"DRUG","name":"insulin detemir","otherNames":[]},{"type":"DRUG","name":"insulin aspart","otherNames":[]},{"type":"DRUG","name":"insulin aspart","otherNames":[]}],"arms":[{"label":"IDegAsp OD","type":"EXPERIMENTAL"},{"label":"IDet","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted in Europe, Oceania, and the United States of America (USA).\n\nThe aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin detemir (IDet) plus insulin aspart in patients with type 1 diabetes (main period) followed by the extension period comparing the long-term safety of NN5401 plus insulin aspart with insulin detemir plus insulin aspart.\n\nThe main period is registered internally at Novo Nordisk as NN5401-3594 while the extension period is registered as NN5401-3645.","primaryOutcome":{"measure":"Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment","timeFrame":"Week 0, Week 26","effectByArm":[{"arm":"IDegAsp OD","deltaMin":-0.73,"sd":0.83},{"arm":"IDet","deltaMin":-0.68,"sd":0.77}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":81,"countries":["United States","Australia","Denmark","France","Israel","Poland","Puerto Rico","Romania","Russia","United Kingdom"]},"refs":{"pmids":["26773446","22933438"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":46,"n":362},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Hypoglycaemia","Headache","Influenza"]}}